Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Considerations When Treating Patients With Metastatic Renal Cell Carcinoma

January 17th 2023

Similar to first-line therapy choices, particular treatment factors, including type and duration of response to prior therapy, pace of disease progression, and toxicities associated with first-line treatment, are all practical considerations that help guide therapy selection in metastatic renal cell carcinoma.

Emerging Data in Non-Clear Cell RCC Treatment

January 16th 2023

Hans Hammers, MD, PhD, reviews emerging data on the challenging treatment of non-clear cell renal cell carcinoma.

COSMIC-313: Frontline Triplet Therapy in Advanced RCC

January 16th 2023

Experts discuss data from the COSMIC-313 study investigating a triplet combination therapy for the frontline treatment of advanced renal cell carcinoma.

Dr. Allaf on Evaluating the PROSPER-RCC Trial Results in RCC

January 12th 2023

Mohamad Ezzeddine Allaf, MD, discusses several key considerations when interpreting and extrapolating initial results from the phase 3 PROSPER-RCC trial in renal cell carcinoma.

Novel Combination Regimens Strengthen and Expand Treatment Paradigm for Genitourinary Cancers

January 10th 2023

Tanya B. Dorff, MD, highlights improvements in the current treatment paradigm for other genitourinary cancers and spotlights efforts being made to expand the role of immunotherapy and targeted therapy combinations.

Nivolumab plus Ipilimumab for Frontline Treatment of Advanced RCC: 5-Year Follow-Up from the CheckMate 214 Trial

January 9th 2023

Dr Moshe Orenstein reviews the 5-year data update of the CheckMate 214 trial in favorable risk subgroups of advanced renal cell carcinoma.

Managing Adverse Events of IO/IO Frontline Combination Therapies in Advanced RCC Treatment

January 9th 2023

Drs Hammers and Orenstein describe how they manage the side effects of IO/IO combination treatments in their patients with advanced renal cell carcinoma.

Dr. Dorff on Second-line Immune Checkpoint Inhibitors in Metastatic RCC

January 4th 2023

Tanya Dorff, MD, discusses remaining questions regarding sequencing in metastatic renal cell carcinoma.

CA-125 May Be the Key to Renal Medullary Carcinoma Treatment

December 28th 2022

Investigators may have discovered a key detail about renal medullary carcinoma that could have significant ramifications for patients.

Triplet Combinations Could Represent Next Frontier in Frontline Metastatic RCC

December 27th 2022

Michael R. Harrison, MD, discusses the key long-term data of select doublet combinations in renal cell carcinoma, the early investigation of triplet therapy in the frontline setting, and more.

Lenvatinib Dosing Strategies in Frontline Advanced RCC Treatment

December 22nd 2022

Hans Hammers, MD, PhD, details his strategies for dosing lenvatinib in patients with advanced renal cell carcinoma.

Updates from the CLEAR Study on Efficacy of Lenvatinib plus Pembrolizumab in Patients with Advanced RCC

December 22nd 2022

Drs Hans Hammers reviews updated efficacy data on the use of lenvatinib plus pembrolizumab for frontline advanced renal cell carcinoma treatment.

Blum Highlights Implications of CA-125 Levels in Renal Medullary Carcinoma

December 19th 2022

Dr Blum discusses renal medullary carcinoma, the lack of approved systemic therapy for these patients, and findings showing a correlation between CA-125 levels and increased tumor burden and treatment response in this disease.

Comparing IO/IO and IO/TKI Frontline Treatment in Advanced RCC

December 15th 2022

Moshe Ornstein, MD, MA, explains his reasoning for starting patients with advanced renal cell carcinoma on an IO/IO combination regimen.

Overview of the Frontline Management and Risk Stratification of Advanced Renal Cell Carcinoma (RCC)

December 15th 2022

Hans Hammers, MD, PhD, describes how patients with advanced renal cell carcinoma are risk-stratified, and the go-to treatment approach for intermediate risk patients.

Pembrolizumab Appears Safe Across Melanoma, NSCLC, RCC in Pooled Analysis

December 8th 2022

Pembrolizumab induced treatment-related adverse effects that were generally mild or moderate in severity, according to finding from a pooled analysis of more than 4000 patients with melanoma, non–small cell lung cancer, or renal cell carcinoma.

FDA Grants Fast Track Designation to Batiraxcept for Advanced or Metastatic Clear Cell RCC

November 30th 2022

The FDA has granted a fast track designation to batiraxcept for the treatment of patients with advanced or metastatic clear cell renal cell carcinoma who have progressed after 1 or 2 prior lines of systemic therapy that include both immuno-oncology–based and VEGF TKI–based therapies, either in combination or sequentially.

PROSPER-RCC Results May Inform Further Research on Neoadjuvant IO Approaches in RCC

November 29th 2022

Mohamad Allaf, MD, discusses innovative and unique aspects of the PROSPER-RCC trial design, areas for continued analysis within the study, and the ways in which this trial will inspire and inform continued research in renal cell carcinoma.

ARRY-614 Plus Immune Checkpoint Inhibition Can Induce Durable Responses in Advanced Solid Tumors

November 28th 2022

The combination of the p38 MAPK inhibitor ARRY-614 plus nivolumab with or without ipilimumab was well tolerated and elicited disease control in high-risk, PD-(L)1–refractory patients with advanced solid tumors.

ADCs Represent One of Many Improvements in GU Cancer Treatment

November 28th 2022

Daniel J. George, MD, discusses the impact that ADCs have had on the evolving treatment landscape of bladder cancer, long-term outcomes with immunotherapy in metastatic renal cell carcinoma, and highlighted current and ongoing research at the Duke Cancer Institute.